Company: PFSA
Filing Date: 2025-05-15
Form Type: 424B3
Source: 0001213900-25-044417
Chunk: 456

Company: Profusa, Inc.
Filing Date: 2025-05-15
Form: 424B3
Chunk 456
---
-Employee Directors: |     |     |     |                                                |
| Joan Braddi             |     |  68 |     | Director                                       |
| Qianye Karen Liu, Ph.D. |     |  54 |     | Director                                       |
| Siu Wai Ng              |     |  38 |     | Director                                       |

Executive Officers Ben C. Hwang, Ph.D.— Dr. Hwang has served as Profusa’s Chairman of the Board and Chief Executive Officer since January 2012. Prior to Profusa, Dr. Hwang served in a variety of leadership roles at Life Technologies Corp. (acquired by Thermo Fisher Scientific, Inc.), including President of the Asia Pacific Region and Head of the qPCR Division. Prior to joining Life Technology, Dr. Hwang was a consultant with McKinsey & Company. Dr. Hwang received his M.A. in Biology and Ph.D. in Biology from The Johns Hopkins University. We believe that Dr. Hwang is well -qualifiedto serve as a director of our company based on his familiarity with Profusa’s business, his experience in the life science industry, and his educational background. Non-Employee Directors Joan Braddi— Ms. Braddi has served as a member of Profusa’s board of directors since December 2015. Ms. Braddi has served in a number of positions at Alphabet Inc. (previously Google, Inc.), a technology company, since May 1999, most recently as Vice President, Partnerships. Ms. Braddi received her B.S. in Business Administration from San Jose State University. Qianye Karen Liu, Ph.D.— Dr. Liu has served as a member of Profusa’s board of directors since December 2015. Dr. Liu has been active in healthcare venture investing since 2005. She is a founding partner of 3E Bioventures Capital, a life science focused VC firm which actively invests in innovative therapeutics as well as cross -disciplinaryhealth tech innovations, which was formed in 2015. Prior to a career in investment, Dr. Liu had a successful Internet start -upexperience and had also worked as a consultant at McKinsey & Company. Dr. Liu currently serves on the boards of directors of 3E BioPartners Ltd., 3E Bioventure Partners, LLC, and Beijing 3E Bioventures Investment Management Co.Ltd. Dr. Liu received a Ph.D. in Immunology from Harvard University, Master of